Fibromyalgia Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Fibromyalgia Treatment Market
The Fibromyalgia Treatment Market size was valued at USD 19.18 billion in 2023, and the market is now projected to grow to 141.4 USD billion by 2032, exhibiting a CAGR of 9.2% during the forecast period of 2023-2030.
As a result of the government's lockdown and other steps to stop the coronavirus from spreading, all supply activities were postponed, which decreased the amount of product related to this domain. This has affected the overall supply and demand chains of the particular market. The market has suffered because fewer patients are seeking therapy for fibromyalgia as a result of the pandemic, which is detrimental because the condition is a less well-known and underdiagnosed indication. These factors affected the Fibromyalgia Treatment Market Growth.
This is the major factor attributing the growth of this particular market. This factor is majorly involved in taking the revenue numbers above the skies and soaring greater heights and also the sales and demands have been proliferation and increased its value to greater extent.The global fibromyalgia treatment market is growing due to a number of causes. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that fibromyalgia affects about five million people in the United States. These particular growth driving factors have been recorded to attribute the Fibromyalgia Treatment Market share. A lot of growth has been observed in the recent times because of this particular factor that contributed and also acted as a catalyst to the overall development of the product market.
A latest trend has been witnessed to proliferate the market growth. This particular trend has been recorded to be the most profiting trends that have been upgraded to augment the overall market growth. A lot of specifications have been made to this particular product which has benefited the market growth. The market for medications used to treat fibromyalgia is expected to increase significantly in the coming years due to the increasing prevalence of the condition. This specific trend has influenced the market growth so much so that the revenue and share numbers of this particular product is touching the skies and soaring over. The expansion of pre-marketed items in the sector is being actively pursued by key companies that are aware of this market potential. For example, a phase 2 clinical trial for the treatment of fibromyalgia is presently underway for Teva Pharmaceuticals' AJOVY, which is already approved in the United States for migraine. It is anticipated that this crucial trend would favorably impact market expansion throughout the course of the projection year.
Comprehensive Analysis of Fibromyalgia Treatment Market
The segmentation of this particular market has been divided and then further subdivided into various categories. Drug class divides the market into muscle relaxants, antidepressants, antiepileptics, and others (including pipeline items). Hospital pharmacies, retail pharmacies, and online pharmacies are all part of the fibromyalgia therapy market, according to the distribution channel segmentation.
This particular region has augmented a lot in the past few years in this particular product market. This specific region held the biggest revenue share. Some of the major Companies includes Numerous factors, including the growing incidence of fibromyalgia, are propelling the market expansion in Europe. Additionally, it is anticipated that the dearth of fibromyalgia treatment alternatives and prospective product introductions will support market expansion in the upcoming years. In addition, it is expected that the European Commission's increase in healthcare funding will support the region's expansion. This particular region has experienced immense proliferation in the market shares and has attributed to the global market revenue.
Global markets are fiercely competitive and highly fragmented. Due to their creative packaging solutions, a few group of large market companies hold a fair amount of market share. Some of the major Companies includes Pfizer, Inc.(U.S.), Eli Lilly and Company (U.S.), Allergan (Ireland), Tonix Pharmaceuticals (U.S.), and Aptinyx (U.S.).
In December 2020, This particular company has attributed the market growth in terms of revenue and shares system. According to Tonix Pharmaceutical, the company's TNX-102 phase 3 research results for the treatment of fibromyalgia were positive. This particular development and investment the global market has been recorded to be a boon for the market growth.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD Million)
Segmentation Drug Class, Distribution Channel, and Region
By Drug Class
Antidepressants
Antiepileptic
Muscle Relaxants
Others (incl. Pipeline Products)
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America
By Drug Class
By Distribution Channel
By Country
USA (By Drug Class)
Canada (By Drug Class)
Europe
By Drug Class
By Distribution Channel
By Country
UK (By Drug Class)
Germany (By Drug Class)
France (By Drug Class)
Italy (By Drug Class)
Spain (By Drug Class)
Scandinavia (By Drug Class)
Rest of Europe (By Drug Class)
Asia Pacific
By Drug Class
By Distribution Channel
By Country
Japan (By Drug Class)
China (By Drug Class)
India (By Drug Class)
Australia (By Drug Class)
Southeast Asia (By Drug Class)
Rest of Asia Pacific (By Drug Class)
Latin America
By Drug Class
By Distribution Channel
By Country
Brazil (By Drug Class)
Mexico (By Drug Class)
Rest of Latin America (By Drug Class)
Middle East & Africa
By Drug Class
By Distribution Channel
By Country
GCC (By Drug Class)
South Africa (By Drug Class)
Rest of MEA (By Drug Class)
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Fibromyalgia by key Regions
- 4.2. Key Industry Trends
- 4.3. Pipeline Analysis
- 4.4. Regulatory Scenario
- 4.5. Recent Industry Developments Such as Mergers & Acquisitions
- 4.6. Impact of COVID-19 on the Market
- 5. Global Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. Antidepressants
- 5.2.2. Antiepileptic
- 5.2.3. Muscle Relaxants
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacy
- 5.3.2. Retail Pharmacy
- 5.3.3. Online Pharmacy
- 5.4. Market Analysis, Insights and Forecast – By Country
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Drug Class
- 6.2.1. Antidepressants
- 6.2.2. Antiepileptic
- 6.2.3. Muscle Relaxants
- 6.2.4. Others
- 6.3. Market Analysis – By Distribution Channel
- 6.3.1. Hospital Pharmacy
- 6.3.2. Retail Pharmacy
- 6.3.3. Online Pharmacy
- 6.4. Market Analysis – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Drug Class
- 6.4.1.1.1. Antidepressants
- 6.4.1.1.2. Antiepileptic
- 6.4.1.1.3. Muscle Relaxants
- 6.4.1.1.4. Others
- 6.4.2. Canada
- 6.4.2.1. By Drug Class
- 6.4.2.1.1. Antidepressants
- 6.4.2.1.2. Antiepileptic
- 6.4.2.1.3. Muscle Relaxants
- 6.4.2.1.4. Others
- 7. Europe Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Drug Class
- 7.2.1. Antidepressants
- 7.2.2. Antiepileptic
- 7.2.3. Muscle Relaxants
- 7.2.4. Others
- 7.3. Market Analysis – By Distribution Channel
- 7.3.1. Hospital Pharmacy
- 7.3.2. Retail Pharmacy
- 7.3.3. Online Pharmacy
- 7.4. Market Analysis – By Country
- 7.4.1. U.K.
- 7.4.1.1. By Drug Class
- 7.4.1.1.1. Antidepressants
- 7.4.1.1.2. Antiepileptic
- 7.4.1.1.3. Muscle Relaxants
- 7.4.1.1.4. Others
- 7.4.2. Germany
- 7.4.2.1. By Drug Class
- 7.4.2.1.1. Antidepressants
- 7.4.2.1.2. Antiepileptic
- 7.4.2.1.3. Muscle Relaxants
- 7.4.2.1.4. Others
- 7.4.3. France
- 7.4.3.1. By Drug Class
- 7.4.3.1.1. Antidepressants
- 7.4.3.1.2. Antiepileptic
- 7.4.3.1.3. Muscle Relaxants
- 7.4.3.1.4. Others
- 7.4.4. Spain
- 7.4.4.1. By Drug Class
- 7.4.4.1.1. Antidepressants
- 7.4.4.1.2. Antiepileptic
- 7.4.4.1.3. Muscle Relaxants
- 7.4.4.1.4. Others
- 7.4.5. Italy
- 7.4.5.1. By Drug Class
- 7.4.5.1.1. Antidepressants
- 7.4.5.1.2. Antiepileptic
- 7.4.5.1.3. Muscle Relaxants
- 7.4.5.1.4. Others
- 7.4.6. Scandinavia
- 7.4.6.1. By Drug Class
- 7.4.6.1.1. Antidepressants
- 7.4.6.1.2. Antiepileptic
- 7.4.6.1.3. Muscle Relaxants
- 7.4.6.1.4. Others
- 7.4.7. Rest of Europe
- 7.4.7.1. By Drug Class
- 7.4.7.1.1. Antidepressants
- 7.4.7.1.2. Antiepileptic
- 7.4.7.1.3. Muscle Relaxants
- 7.4.7.1.4. Others
- 8. Asia Pacific Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Drug Class
- 8.2.1. Antidepressants
- 8.2.2. Antiepileptic
- 8.2.3. Muscle Relaxants
- 8.2.4. Others
- 8.3. Market Analysis – By Distribution Channel
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail Pharmacy
- 8.3.3. Online Pharmacy
- 8.4. Market Analysis – By Country
- 8.4.1. Japan
- 8.4.1.1. By Drug Class
- 8.4.1.1.1. Antidepressants
- 8.4.1.1.2. Antiepileptic
- 8.4.1.1.3. Muscle Relaxants
- 8.4.1.1.4. Others
- 8.4.2. China
- 8.4.2.1. By Drug Class
- 8.4.2.1.1. Antidepressants
- 8.4.2.1.2. Antiepileptic
- 8.4.2.1.3. Muscle Relaxants
- 8.4.2.1.4. Others
- 8.4.3. India
- 8.4.3.1. By Drug Class
- 8.4.3.1.1. Antidepressants
- 8.4.3.1.2. Antiepileptic
- 8.4.3.1.3. Muscle Relaxants
- 8.4.3.1.4. Others
- 8.4.4. Australia
- 8.4.4.1. By Drug Class
- 8.4.4.1.1. Antidepressants
- 8.4.4.1.2. Antiepileptic
- 8.4.4.1.3. Muscle Relaxants
- 8.4.4.1.4. Others
- 8.4.5. Southeast Asia
- 8.4.5.1. By Drug Class
- 8.4.5.1.1. Antidepressants
- 8.4.5.1.2. Antiepileptic
- 8.4.5.1.3. Muscle Relaxants
- 8.4.5.1.4. Others
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Drug Class
- 8.4.6.1.1. Antidepressants
- 8.4.6.1.2. Antiepileptic
- 8.4.6.1.3. Muscle Relaxants
- 8.4.6.1.4. Others
- 9. Latin America Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Drug Class
- 9.2.1. Antidepressants
- 9.2.2. Antiepileptic
- 9.2.3. Muscle Relaxants
- 9.2.4. Others
- 9.3. Market Analysis – By Distribution Channel
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail Pharmacy
- 9.3.3. Online Pharmacy
- 9.4. Market Analysis – By Country
- 9.4.1. Brazil
- 9.4.1.1. By Drug Class
- 9.4.1.1.1. Antidepressants
- 9.4.1.1.2. Antiepileptic
- 9.4.1.1.3. Muscle Relaxants
- 9.4.1.1.4. Others
- 9.4.2. Mexico
- 9.4.2.1. By Drug Class
- 9.4.2.1.1. Antidepressants
- 9.4.2.1.2. Antiepileptic
- 9.4.2.1.3. Muscle Relaxants
- 9.4.2.1.4. Others
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Drug Class
- 9.4.3.1.1. Antidepressants
- 9.4.3.1.2. Antiepileptic
- 9.4.3.1.3. Muscle Relaxants
- 9.4.3.1.4. Others
- 10. Middle East & Africa Fibromyalgia Treatment Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Drug Class
- 10.2.1. Antidepressants
- 10.2.2. Antiepileptic
- 10.2.3. Muscle Relaxants
- 10.2.4. Others
- 10.3. Market Analysis – By Distribution Channel
- 10.3.1. Hospital Pharmacy
- 10.3.2. Retail Pharmacy
- 10.3.3. Online Pharmacy
- 10.4. Market Analysis – By Country
- 10.4.1. GCC
- 10.4.1.1. By Drug Class
- 10.4.1.1.1. Antidepressants
- 10.4.1.1.2. Antiepileptic
- 10.4.1.1.3. Muscle Relaxants
- 10.4.1.1.4. Others
- 10.4.2. South Africa
- 10.4.2.1. By Drug Class
- 10.4.2.1.1. Antidepressants
- 10.4.2.1.2. Antiepileptic
- 10.4.2.1.3. Muscle Relaxants
- 10.4.2.1.4. Others
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Drug Class
- 10.4.3.1.1. Antidepressants
- 10.4.3.1.2. Antiepileptic
- 10.4.3.1.3. Muscle Relaxants
- 10.4.3.1.4. Others
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.5.1. Pfizer, Inc.
- 11.5.1.1. Overview,
- 11.5.1.2. Products & services,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. Eli Lilly and Company
- 11.5.2.1. Overview,
- 11.5.2.2. Products & services,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. Allegran
- 11.5.3.1. Overview,
- 11.5.3.2. Products & services,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. Tonix Pharmaceuticals
- 11.5.4.1. Overview,
- 11.5.4.2. Products & services,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. Aptinyx
- 11.5.5.1. Overview,
- 11.5.5.2. Products & services,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. Teva Pharmaceutical Industries Ltd.
- 11.5.6.1. Overview,
- 11.5.6.2. Products & services,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Novartis AG
- 11.5.7.1. Overview,
- 11.5.7.2. Products & services,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. Sun Pharmaceuticals
- 11.5.8.1. Overview,
- 11.5.8.2. Products & services,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. Astella Pharma Inc
- 11.5.9.1. Overview,
- 11.5.9.2. Products & services,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 11.5.10. Other Prominent Players
- 11.5.10.1. Overview,
- 11.5.10.2. Products & services,
- 11.5.10.3. SWOT analysis,
- 11.5.10.4. Recent developments,
- 11.5.10.5. strategies,
- 11.5.10.6. financials (based on availability)
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook